Brokerages Set Catabasis Pharmaceuticals Inc (CATB) Target Price at $4.82
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has earned a consensus rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $4.82.
CATB has been the subject of several research reports. Citigroup upgraded shares of Catabasis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $3.00 target price for the company in a report on Monday, November 20th. Zacks Investment Research downgraded shares of Catabasis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, October 16th. Oppenheimer raised their price target on shares of Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the company an “outperform” rating in a research report on Thursday, October 5th. CIBC reissued an “outperform” rating and issued a $7.00 price target (up previously from $4.00) on shares of Catabasis Pharmaceuticals in a research report on Thursday, October 5th. Finally, Cowen reissued a “market perform” rating and issued a $2.00 price target on shares of Catabasis Pharmaceuticals in a research report on Friday, October 6th.
Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC purchased a new position in Catabasis Pharmaceuticals in the 1st quarter valued at approximately $106,000. Oppenheimer & Co. Inc. boosted its position in Catabasis Pharmaceuticals by 33.3% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 30,000 shares during the period. Virtu KCG Holdings LLC purchased a new position in Catabasis Pharmaceuticals in the 2nd quarter valued at approximately $271,000. Finally, Wedbush Securities Inc. boosted its position in Catabasis Pharmaceuticals by 2,368.6% in the 3rd quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock valued at $534,000 after buying an additional 241,602 shares during the period. 33.14% of the stock is owned by institutional investors.
Catabasis Pharmaceuticals (CATB) traded up $0.03 during trading on Thursday, reaching $1.79. Catabasis Pharmaceuticals has a one year low of $1.08 and a one year high of $5.51.
Catabasis Pharmaceuticals (NASDAQ:CATB) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. The company had revenue of $0.25 million during the quarter. analysts anticipate that Catabasis Pharmaceuticals will post -1.39 EPS for the current year.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.